Skip to main content

Table 6 For the group with Probable Diabetes in 2014, comparison of characteristic variables between baseline in 2014 and follow-up in 2019

From: Incidence of diabetes and its predictors in the Greater Beirut Area: a five-year longitudinal study

 

2014 N = 42

2019 N = 42

p-value

Age (years)

54.5 ± 11.0

59.0 ± 10.9

 < 0.0001

Lifestyle and anthropometric

 Smoking

  

1.00

  Never

9 (21.5)

9 (21.5)

  Current

25 (59.5)

25 (59.5)

  Former

8 (19.0)

8 (19.0)

 Sleep apnea index

  

1.00

  Low risk

17 (50.0)

19 (45.2)

  High risk

17 (50.0)

23 (54.8)

 Any Physical activity

36 (85.7)

31 (73.8)

0.18

 Physical activity status

  

0.86

  Low

21 (50.0)

23 (54.8)

  Moderate

17 (40.5)

16 (38.1)

  High

4 (9.5)

3 (7.1)

 BMI

33.3 ± 7.1

32.8 ± 7.0

0.14

 Systolic blood pressure mmHg

131.6 ± 21.7

134.7 ± 22.5

0.47

 Diastolic blood pressure mmHg

79.2 ± 10.0

79.6 ± 11.0

0.87

Medication intake

 Anti-hypertensive intake

17 (40.5)

29 (69.0)

0.002

 Cholesterol medication

6 (14.3)

17 (40.5)

0.003

 Diabetes medications

  None (diet only)

  Oral hypoglycemic#

25 (59.5)

16 (38.1)

11 (26.2)

29 (69.0)

0.001

  Insulin

0 (0.0)

0 (0.0)

−

  Combination *

1 (2.4)

2 (4.8)

1.00

Laboratory measures

 HBA1C (%)

7.4 ± 1.7

7.5 ± 1.9

0.56

 Proportion HbA1C

  

0.29

   < 7

21 (50.0)

20 (47.6)

  7–9

16 (38.1)

14 (33.3)

   ≥ 9

5 (11.9)

8 (19.0)

 fasting plasma glucose (mg/DL)

147.4 ± 44.3

165.0 ± 59.5

0.04

 Triglyceride (mg/dL)

178.8 ± 66.2

185.4 ± 72.8

0.42

 LDL (mg/dL)

109.4 ± 39.3

105.4 ± 42.2

0.53

 HDL-C (mg/dL)

46.0 ± 13.1

45.0 ± 12.3

0.50

 Urine microalbumin/creatinine ratio (ug/gm)

18.1 (32.8)

31.7 (56.8)

0.05

  1. Significance was considered at a p value < 0.05
  2. *Combination refers to oral hypoglycemic agents with insulin
  3. #Oral hypoglycemic classes were for the majority sulfonylureas with metformin [8], or with pioglitazone [1], metformin alone [6], or single DPP4 inhibitor [1] in 2014. In 2019, the most common classes remain metformin [8] with sulfonylureas [8]; however, there is an increase in use of DPP4 inhibitors in combination with other classes [7], pioglitazone [1], new use of SGLT2 inhibitors [2] and others (3)